Cargando…

A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor. Despite the advances in surgery, radiotherapy and chemotherapy, patient survival averages only 14.6 months. In most GBM tumors, tyrosine kinases show increased activity and/or expression and actively contribute to t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nehoff, Hayley, Parayath, Neha N., McConnell, Melanie J., Taurin, Sebastien, Greish, Khaled
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741976/ https://www.ncbi.nlm.nih.gov/pubmed/26517812

Ejemplares similares

Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect
por: Nehoff, Hayley, et al.
Publicado: (2014)

Styrene maleic acid micelles as a nanocarrier system for oral anticancer drug delivery – dual uptake through enterocytes and M-cells
por: Parayath, Neha N, et al.
Publicado: (2015)

Styrene maleic acid-encapsulated paclitaxel micelles: antitumor activity and toxicity studies following oral administration in a murine orthotopic colon cancer model
por: Parayath, Neha N, et al.
Publicado: (2016)

A Novel Role for Raloxifene Nanomicelles in Management of Castrate Resistant Prostate Cancer
por: Taurin, Sebastien, et al.
Publicado: (2014)

A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer
por: Archibald, Monica, et al.
Publicado: (2016)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery
por: Brar, Harpinder K., et al.
Publicado: (2022)

Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors
por: El-Dabh, Ashraf, et al.
Publicado: (2019)

Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme
por: Tilak, Manali, et al.
Publicado: (2021)

ALK and IGF-1R as independent targets in crizotinib resistant lung cancer
por: Wilson, Christabel, et al.
Publicado: (2017)

Theory and applications of nonparenteral nanomedicines
por: Kesharwani, Prashant, et al.
Publicado: (2020)

The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation
por: Vandyke, K, et al.
Publicado: (2011)

Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib
por: Bielec, Bjoern, et al.
Publicado: (2020)

Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis
por: Guo, Kai, et al.
Publicado: (2019)

Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors
por: Yuan, Jie, et al.
Publicado: (2018)

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
por: Hennigs, Jan K, et al.
Publicado: (2011)

Enhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer
por: Bahman, Fatemah, et al.
Publicado: (2021)

Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia
por: Ciaffaglione, Valeria, et al.
Publicado: (2022)

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
por: Wang, Wenxian, et al.
Publicado: (2016)

Stable Fatty Acid Solvates of Dasatinib, a Tyrosine Kinase Inhibitor: Prediction, Process, and Physicochemical Properties
por: Saladi, Venkata Narasayya, et al.
Publicado: (2022)

The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice
por: Gu, Yue, et al.
Publicado: (2023)

Oral Insulin Delivery Using Poly (Styrene Co-Maleic Acid) Micelles in a Diabetic Mouse Model
por: Bahman, Fatemah, et al.
Publicado: (2020)

Inhibition of aquaporins as a potential adjunct to breast cancer cryotherapy
por: Alkhalifa, Haifa, et al.
Publicado: (2021)

Retraction Note: Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors
por: Yuan, Jie, et al.
Publicado: (2021)

The Tyrosine Kinase Inhibitor Dasatinib Induces a Marked Adipogenic Differentiation of Human Multipotent Mesenchymal Stromal Cells
por: Borriello, Adriana, et al.
Publicado: (2011)

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines
por: Lu, Liu, et al.
Publicado: (2018)

Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging
por: Rodríguez-Agustín, Andrea, et al.
Publicado: (2023)

Evaluation of Tyrosine Kinase Inhibitor Combinations for Glioblastoma Therapy
por: Joshi, Avadhut D., et al.
Publicado: (2012)

Styrene maleic acid-encapsulated RL71 micelles suppress tumor growth in a murine xenograft model of triple negative breast cancer
por: Martey, Orleans, et al.
Publicado: (2017)

Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme
por: Lubanska, Dorota, et al.
Publicado: (2017)

Innate T-αβ lymphocytes as new immunological components of anti-tumoral “off-target” effects of the tyrosine kinase inhibitor dasatinib
por: Barbarin, Alice, et al.
Publicado: (2020)

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
por: Häselbarth, Lukas, et al.
Publicado: (2023)

Glioblastoma Multiforme
por: Sheehan, Jonas M., et al.
Publicado: (2012)

Crizotinib targets in glioblastoma stem cells
por: Junca, Audelaure, et al.
Publicado: (2017)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
por: Aldaz, Paula, et al.
Publicado: (2021)

Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-d]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme
por: Poggialini, Federica, et al.
Publicado: (2023)

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases
por: Liu, Yuanbo, et al.
Publicado: (2010)

Glioblastoma multiforme – an overview
por: Urbańska, Kaja, et al.
Publicado: (2014)

Incidentalomas to glioblastoma multiforme
por: Sachdev, Bobby, et al.
Publicado: (2014)

Significant Effect of Anti-tyrosine Kinase Inhibitor (Gefitinib) on Overall Survival of the Glioblastoma Multiforme Patients in the Backdrop of Mutational Status of Epidermal Growth Factor Receptor and PTEN Genes
por: Arif, Sajad Hussain, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qiib8c50nc0v01s7n2ovetlstc